Effectiveness of a Physical Exercise Prescription Program in Primary Care for Adults Aged 65 and … (NCT07394790) | Clinical Trial Compass
RecruitingNot Applicable
Effectiveness of a Physical Exercise Prescription Program in Primary Care for Adults Aged 65 and Older: PREFIS-AP
Spain210 participantsStarted 2026-02-09
Plain-language summary
This randomized controlled trial aims to evaluate the effectiveness of an individualized Physical Exercise Prescription Program delivered in Primary Care for adults aged 65 years and older. The intervention includes a structured assessment of physical fitness, muscle function and mass, physical activity level, and quality of life, followed by a tailored exercise plan encompassing aerobic, strength, respiratory, flexibility, and balance training. Outcomes will be compared with a control group receiving standard health advice to walk briskly for at least 30 minutes daily. The study also explores associations between polypharmacy, muscle function, physical performance, and quality of life.
Who can participate
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 65 years
* Motivated to participate and able to provide informed consent
* Able to attend baseline assessment and follow-up
* Clinical stability allowing participation in exercise evaluation
Exclusion Criteria:
* Recent myocardial infarction
* Unstable angina
* Uncontrolled arrhythmias (symptomatic or hemodynamically compromising)
* Syncope
* Acute endocarditis, myocarditis, or pericarditis
* Severe or symptomatic aortic stenosis
* Uncontrolled heart failure
* Recent pulmonary thromboembolism or pulmonary infarction
* Lower-limb thrombosis
* Severe aortic stenosis or suspected dissecting aortic aneurysm
* Uncontrolled asthma
* Pulmonary edema
* Acute respiratory failure
* Acute non-cardiopulmonary illness that impairs exercise capacity (e.g., infection, thyrotoxicosis, acute renal failure)
* Mental disorder that prevents adequate cooperation.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Quality of Life
Timeframe: Baseline to 3 months.
Trial details
NCT IDNCT07394790
SponsorInstituto de Investigación Biomédica de Salamanca